Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Bernhard Hemmer

Showing results (1-10 of 390) with videos related to

Pageof 39
Sort By:
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 14, 2015
Antibodies to the inward rectifying potassium channel 4.1 in multiple sclerosis: different methodologies--conflicting results?Bernhard Hemmer
Handbook of Clinical Neurology|January 12, 2026
Evolving targeted biologics against T cells, cytokines, and intracellular immune targets for multiple sclerosis with implications in other autoimmune neurologic diseasesBernhard Hemmer
Journal of Neurology|June 4, 2011
Treatment of multiple sclerosis: current concepts and future perspectivesDorothea Buck, Bernhard Hemmer
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 27, 2012
Time to talk about timing--when to start, stop and change anti-migratory drugs in MSOlaf Stüve, Bernhard Hemmer
Nature Clinical Practice. Neurology|January 31, 2007
Revised criteria for neuromyelitis optica--a new diagnostic standard?Bernhard Hemmer, Olaf Stüve
Molecular Immunology|March 24, 2004
Specificity and degeneracy: T cell recognition in CNS autoimmunityDun Zhou, Bernhard Hemmer
Neurology|August 8, 2013
Hunting for autoantibodies in multiple sclerosisBernhard Hemmer, Rajneesh Srivastava
Expert Opinion on Biological Therapy|March 14, 2017
Daclizumab for the treatment of relapsing-remitting multiple sclerosisMarina Herwerth, Bernhard Hemmer
Nature Reviews. Neurology|January 21, 2017
Multiple sclerosis in 2016: Immune-directed therapies in MS - efficacy and limitationsBernhard Hemmer, Mark Mühlau
Nature Clinical Practice. Neurology|March 6, 2009
Should we measure the bioavailability of interferon beta in vivo in patients with multiple sclerosis?Bernhard Hemmer, Achim Berthele
Pageof 39

Showing results (1-10 of 390) with videos related to

Sort By:
Pageof 39
Multiple Sclerosis (Houndmills, Basingstoke, England)|January 14, 2015
Antibodies to the inward rectifying potassium channel 4.1 in multiple sclerosis: different methodologies--conflicting results?Bernhard Hemmer
Handbook of Clinical Neurology|January 12, 2026
Evolving targeted biologics against T cells, cytokines, and intracellular immune targets for multiple sclerosis with implications in other autoimmune neurologic diseasesBernhard Hemmer
Journal of Neurology|June 4, 2011
Treatment of multiple sclerosis: current concepts and future perspectivesDorothea Buck, Bernhard Hemmer
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 27, 2012
Time to talk about timing--when to start, stop and change anti-migratory drugs in MSOlaf Stüve, Bernhard Hemmer
Nature Clinical Practice. Neurology|January 31, 2007
Revised criteria for neuromyelitis optica--a new diagnostic standard?Bernhard Hemmer, Olaf Stüve
Molecular Immunology|March 24, 2004
Specificity and degeneracy: T cell recognition in CNS autoimmunityDun Zhou, Bernhard Hemmer
Neurology|August 8, 2013
Hunting for autoantibodies in multiple sclerosisBernhard Hemmer, Rajneesh Srivastava
Expert Opinion on Biological Therapy|March 14, 2017
Daclizumab for the treatment of relapsing-remitting multiple sclerosisMarina Herwerth, Bernhard Hemmer
Nature Reviews. Neurology|January 21, 2017
Multiple sclerosis in 2016: Immune-directed therapies in MS - efficacy and limitationsBernhard Hemmer, Mark Mühlau
Nature Clinical Practice. Neurology|March 6, 2009
Should we measure the bioavailability of interferon beta in vivo in patients with multiple sclerosis?Bernhard Hemmer, Achim Berthele
Pageof 39